Compare PUBM & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PUBM | PROK |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.5M | 417.1M |
| IPO Year | 2020 | N/A |
| Metric | PUBM | PROK |
|---|---|---|
| Price | $9.21 | $2.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $18.45 | $6.25 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $288,382,000.00 | $744,000.00 |
| Revenue This Year | N/A | $918.66 |
| Revenue Next Year | $0.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.01 | $0.46 |
| 52 Week High | $17.32 | $7.13 |
| Indicator | PUBM | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 54.40 | 44.95 |
| Support Level | $8.91 | $2.04 |
| Resistance Level | $9.24 | $2.25 |
| Average True Range (ATR) | 0.35 | 0.19 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 61.62 | 45.90 |
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.